Current race in the development of DAAs
โ
De Clercq, Erik
๐
Article
๐
2014
๐
Elsevier Science
๐
English
โ 472 KB
The direct-acting antivirals (DAAs) currently in development for treatment of hepatitis C fall into four categories: (i) NS3/4A protease inhibitors: ABT-450/r, faldaprevir, asunaprevir, GS-9256, vedroprevir (GS-9451), danoprevir, MK-5172, vaniprevir, sovaprevir, ACH-2684, narlaprevir and simeprevir,